Seres Therapeutics Inc. (MCRB) |
|
28.4 0.09 (0.32%)
|
10-01 09:30 |
|
Open: |
28.98 |
Pre. Close: |
28.31 |
|
High:
|
28.4 |
Low:
|
28.29 |
|
Volume:
|
8,765 |
Market Cap:
|
2,536M |
|
|
|
|
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 145 full-time employees. The firm is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The firm's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The firm is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The firm is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
29.504 - 29.623 |
29.623 - 29.746 |
|
Low:
|
26.232 - 26.345 |
26.345 - 26.462 |
|
Close:
|
28.372 - 28.582 |
28.582 - 28.798 |
|
Technical analysis |
as of: 2020-09-30 4:43:57 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 34.41  One year: 40.19 |
| Support: |
Support1: 24.87 Support2: 22.03 |
| Resistance: |
Resistance1: 29.46 Resistance2: 34.41 |
| Pivot: |
26.31 |
| Moving Average: |
MA(5): 26.49 MA(20): 25.89
MA(100): 12.18 MA(250): 7.00 |
| MACD: |
MACD(12,26): 1.77 Signal(9): 2.10  |
| Stochastic oscillator: |
%K(14,3): 74.98 %D(3): 65.78 |
| RSI: |
RSI(14): 67.94 |
| 52-week: |
High: 33.00 Low: 2.52 Change(%): 700.3 |
| Average Vol(K): |
3-Month: 311171 10-Days: 73994 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.MCRB has closed above the upper band by 5.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 30 Sep 2020
Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) gained 17.4% in a month. - Marketing Sentinel
Wed, 30 Sep 2020
Seres Therapeutics Inc. (MCRB) went up 7.28% yesterday: Is this the Most Sought-After Stock Today? - News Daemon
Wed, 30 Sep 2020
Highlights from the Ratings and Financial Report for Seres Therapeutics Inc. (MCRB) - The News Heater
Tue, 29 Sep 2020
Seres Therapeutics Inc. (MCRB) Soars 7.28% on September 29 - equities.com
Tue, 29 Sep 2020
Is Seres Therapeutics Inc (MCRB) Stock a Great Value? - InvestorsObserver
Tue, 29 Sep 2020
Zacks: Brokerages Expect Seres Therapeutics Inc (NASDAQ:MCRB) Will Post Quarterly Sales of $9.15 Million - MarketBeat
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
89 |
| Shares Float (M) |
51 |
|
% Held by Insiders
|
10.00 |
|
% Held by Institutions
|
80.15 |
|
Shares Short (K)
|
5,240 |
|
Shares Short P. Month (K)
|
8,920 |
Stock Financials |
|
EPS
|
-1.070 |
|
EPS Est This Year
|
-2.510 |
|
EPS Est Next Year
|
-2.860 |
|
Book Value (p.s.)
|
-0.870 |
|
Profit Margin
|
-262.34 |
|
Operating Margin
|
-265.21 |
|
Return on Assets (ttm)
|
-38.8 |
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
-51.8 |
|
Gross Profit (p.s.)
|
-0.511 |
|
Sales Per Share
|
0.324 |
|
EBITDA (p.s.)
|
-0.778 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-82 |
|
Levered Free Cash Flow (M)
|
-36 |
Stock Valuations |
|
PE Ratio
|
-26.70 |
|
PEG Ratio
|
|
|
Price to Book value
|
-32.84 |
|
Price to Sales
|
88.30 |
|
Price to Cash Flow
|
-31.05 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
